Mass eradication ofHelicobacter pylorito reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands

Abstract

ObjectiveAlthough mass eradication of Helicobacter pylori has been proposed as a means to eliminate gastric cancer, its long-term effects remain unclear.DesignMass eradication of H. pylori infection was launched in 2004 and continued until 2018 for a high-risk Taiwanese population aged 30 years or older dwelling on Matsu Islands with prevalent H. pylori infection. Test positives for the 13C-urea breath test underwent eradication therapy. We evaluated the effectiveness of the mass eradication in reducing two main outcomes, incidence and mortality rates of gastric cancer, until the end of 2016 and 2018, respectively.ResultsAfter six rounds of mass screening and eradication, the coverage rate reached 85.5% (6512/7616). The referral rate for treatment was 93.5% (4286/4584). The prevalence rates of H. pylori fell from 64.2% to 15.0% with reinfection rates of less than 1% per person-year. The presence and severity of atrophic gastritis and intestinal metaplasia also decreased with time. Compared with the historical control period from 1995 to 2003, the effectiveness in reducing gastric cancer incidence and mortality during the chemoprevention period was 53% (95% CI 30% to 69%, p<0.001) and 25% (95% CI −14% to 51%, p=0.18), respectively. No significant changes were noted in the incidence rates of other digestive tract cancers or the antibiotic resistance rate of H. pylori.ConclusionPopulation-based eradication of H. pylori has significantly reduced gastric cancer incidence with no increase in the likelihood of adverse consequences. A significant reduction in mortality is likely to be achieved with a longer follow-up period.Trial registration numberNCT00155389

Whole family—based Helicobacter pylori eradication is a superior strategy to single‐infected patient treatment approach: A systematic review and meta‐analysis

“…The current international consensus reports have recommended to treat all H . pylori ‐infected individuals unless there are contradictory concerns 4‐7 ; and Houston Consensus Conference on Testing for H . pylori Infection in the United State have suggested H .…”

“…In addition to treating infected patients, preventing new infection and reducing recurrence or re‐infection are equally important for H . pylori ‐infection control 6,8 …”

Antibiotic Resistance of Helicobacter Pylori and Influencing Factors in Yangzhou, China: a Cross-sectional Study

“…Yangzhou is located in the middle of Jiangsu province, which has a high stomach cancer incidence of 44.05/100000 in 2014 [28]. H. pylori infection is regarded as the major risk factor of stomach cancer, a long-term cohort study [29] from Taiwan, China showed that eradicating H. pylori can reduce gastric cancer incidence and mortality. Unfortunately, the high prevalence of H. pylori infection and the increasing antibiotic resistance constitute the main challenge for current treatment.…”

Risk stratification for gastric cancer after Helicobacter pylori eradication: A population‐based study on Matsu Islands

“…During 2004–2018, six rounds of mass eradication of H. pylori occurred. The details of this mass eradication program have been reported previously, 3 the short‐term benefits were evaluated in 2008, 4 and the program was fully implemented on a biennial basis 17 …”

“…The H. pylori infection was determined using the 13 C‐urea breath test, those testing positive received eradication treatment, and those who failed initial treatment were retreated 18 . The prevalence of H. pylori infection in the Matsu Islands declined from 64.2% before the mass eradication program to ~10% recently 17 …”